Exclusive Summary

• Holds top-tier US-FDA and PIC/S GMP certifications, enabling fast-track regulatory mutual recognition and providing a decisive quality edge in government tenders across emerging markets.
• Targets a massive demographic of over 210 million aging men globally suffering from BPH, serving as an indispensable first-line chronic therapy with stable, long-term demand.
• Combines China's supply chain cost efficiencies with premium FDA-equivalent quality to maximize distributor profit margins and tender success rates against the originator.